Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

OCUL Insider Trading

OCULAR THERAPEUTIX, INC | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at OCULAR THERAPEUTIX, INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2019-03-14 23:14 2019-03-13 LINDSTROM RICHARD L MD Director BUY $4.33 56,441 $244,390 100,000 +129.6%
2018-12-18 16:52 2018-12-14 Hanley Kevin F. Officer - See Remarks BUY $5.50 10,000 $55,000 20,000 +100.0%
2018-12-13 00:35 2018-12-10 Hanley Kevin F. Officer - SEE REMARKS BUY $5.60 10,000 $56,000 10,000 +100.0%
2018-12-11 00:15 2018-12-06 Bollag Daniel M Officer - See Remarks BUY $5.76 17,400 $100,224 42,100 +70.4%
2018-08-21 23:30 2018-08-20 Mattessich Antony C. Director, Officer - President & CEO BUY $5.95 20,000 $119,000 57,900 +52.8%
2018-08-16 00:13 2018-08-14 Notman Donald Officer - Chief Financial Officer BUY $6.29 12,500 $78,625 17,300 +260.4%
2018-08-13 23:43 2018-08-10 Mattessich Antony C. Director, Officer - President and CEO BUY $6.23 16,900 $105,287 37,900 +80.5%
2017-12-14 01:15 2017-12-12 Mattessich Antony C. Director, Officer - President and C.E.O. BUY $4.29 21,000 $90,090 21,000 +100.0%
2017-12-09 00:27 2017-12-07 Notman Donald Officer - Chief Financial Officer BUY $4.00 4,800 $19,200 4,800 +100.0%
2017-12-09 00:26 2017-12-06 Bollag Daniel M Officer - See Remarks BUY $3.93 24,700 $97,071 24,700 +100.0%
2017-11-20 16:04 2017-11-16 Sawhney Amarpreet Director, Officer, 10% owner - Exec. Chairman of the Board BUY $5.18 19,000 $98,420 696,390 +2.8%
2016-12-17 00:04 2016-12-15 Sawhney Amarpreet Director, Officer, 10% owner - President and CEO BUY $7.85 45,300 $355,605 677,390 +7.2%
2016-06-10 23:30 2016-06-09 Sawhney Amarpreet Director, Officer, 10% owner - President and CEO BUY $6.70 10,000 $67,000 573,733 +1.8%
2015-11-19 04:24 2015-11-17 Sawhney Amarpreet Director, Officer, 10% owner - President and CEO BUY $8.25 10,000 $82,500 563,733 +1.8%
2015-09-17 23:05 2015-09-15 Fortune James Officer - Chief Operating Officer SELL $17.16 9,470 $162,505 112,060 -7.8%
2015-09-16 23:06 2015-09-14 Sawhney Amarpreet Director, Officer, 10% owner - President and CEO BUY $16.50 15,000 $247,457 553,733 +2.8%
2015-06-16 00:51 2015-06-15 Versant Venture Capital III, L.P. 10% owner SELL $22.00 320,000 $7,040,000 13,007 -96.1%
2015-06-16 00:45 2015-06-15 Warden Charles M Director, 10% owner SELL $22.00 320,000 $7,040,000 13,007 -96.1%
2015-06-12 00:24 2015-06-10 Versant Venture Capital III, L.P. 10% owner SELL $22.00 427,000 $9,394,000 14,885 -96.6%
2015-06-12 00:29 2015-06-10 SVLSF IV, LLC 10% owner SELL $22.00 1,119,000 $24,618,000 61,084 -94.8%
2015-06-12 00:24 2015-06-10 Warden Charles M Director, 10% owner SELL $22.00 427,000 $9,394,000 14,885 -96.6%
2015-03-07 02:56 2014-07-30 Ankerud Eric Officer - See Remarks BUY $13.00 1,000 $13,000 78,651 +1.3%
2015-02-05 00:30 2015-02-02 Polaris Venture Management Co. V, L.L.C. 10% owner SELL $29.50 500,000 $14,750,000 19,588 -96.2%
2014-08-09 00:03 2014-07-30 CHV II, L.P. 10% owner BUY $13.00 153,846 $1,999,998 2,100,138 +7.9%
2014-08-01 00:33 2014-07-30 Sawhney Amarpreet Director, Officer, 10% owner - President and CEO BUY $13.00 76,922 $999,986 471,784 +19.5%
2014-07-31 23:14 2014-07-30 SVLSF IV, LLC 10% owner BUY $13.00 715,380 $9,299,940 71,381 +100.0%
SHOW ENTRIES

How to Interpret $OCUL Trades

Not every insider transaction in OCULAR THERAPEUTIX, INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $OCUL shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for OCUL

Insider activity data for OCULAR THERAPEUTIX, INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $OCUL, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.